Source

Human CD27 Ligand, Fc Tag (H-CD27L-1) is expressed from human 293 cells (HEK293). It contains AA Gln 39 - Pro 193 (Accession # P32970-1).

Predicted N-terminus: Pro

Molecular Characterization

This protein carries a human IgG1 Fc tag at the N-terminus.

Endotoxin

Less than 0.01 EU/mg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Bioactivity

ELISA ；

BIACORE (With our Research Grade Biosimilar Antibody products);

Formulation

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

No activity loss was observed after storage at:

4-8°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

Background

Cluster of Differentiation 70 (CD70) is also known as CD27 ligand (CD27L / CD27LG), TNFSF7, TNFSF7G, is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and is a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 on T cells provides costimulatory signals that are required for T cell proliferation, clonal expansion and the promotion of effector T cell formation. CD70 on mouse B cell has been shown to inhibit terminal differentiation of activated B cells into plasma cells and enhances commitment to memory B cell responses. CD70 induces proliferation and IFNγ production, on NK cells.

Reference

(1) McEarchern JA. et al., 2008, Clin Cancer Res., 14(23):7763-72.

(2) Croft M., 2003, Nat Rev Immunol., 3(8):609-20.

(3) Kobata, TS. et al., 1995, Proc. Natl. Acad. Sci. USA, 92: 11249–11253.

(4) Raman V.S. et al., 2003, J Immunol., 171(11):5876-81.

(5) Takeda, K. et al., 2000, J Immunol., 15;164(4):1741-5.